Selexis signed a commercial license agreement with Ganymed Pharmaceuticals for use of Selexis' technology for large-scale production of Ganymed's lead antibodies.
The deal allows Ganymed to use a high performance cell line, developed by Ganymed scientists using the Selexis SURE cell line development platform, for the clinical and commercial production of a number of products.